



PRESS RELEASE

New Managing Director at Aenova site in Marburg, Germany

- **Effective March 01, 2023, Dr. Hanno Scheffczik has been appointed as the new Managing Director of Temmler Pharma GmbH, a member of the Aenova Group.**
- **The experienced general manager leads the site in Marburg with 150 employees and a focus on complex conventional solids and narcotics.**

Marburg, 01 March 2023 - The Aenova Group is a leading international contract manufacturer and developer for the pharmaceutical and healthcare industry with 16 locations and around 4,200 employees worldwide. Temmler Pharma GmbH, a member of the Aenova Group, stands out within the group as a competence center for complex conventional solids and narcotics. With around 150 employees, the Aenova site in Marburg manufactures delayed-release tablets and capsules as well as moisture-sensitive dosage forms. Dr. Hanno Scheffczik has been appointed as the new Managing Director as of March 01, 2023. He replaces the long-standing managing director Dr. Alfred Veit, who is retiring.

Dr. Hanno Scheffczik studied chemistry with a focus on biochemistry and earned his doctorate at the Institute of Virology at Philipps University in Marburg. After holding various development and management positions at well-known, international research-based pharmaceutical companies, he joined Aenova in 2021, initially as Head of Manufacturing Science & Technology. "I am looking forward to my tasks in Marburg and to working with a highly competent and committed team!", says Dr. Scheffczik.

The Aenova site in Marburg has a history of over a century in pharmaceutical development and production and is one of the larger local employers. The company has particular expertise in the development and production of complex pellets with controlled release of active ingredients, such as encapsulated mini-tablets and multi-unit pellet systems (MUPS).

This is aimed at improving the bioavailability of active pharmaceutical ingredients and is an example of the innovative strength of the Aenova site in Marburg. The site is GMP and FDA certified, among others.

"With Dr. Scheffczik we have a long-standing experienced manager and expert who knows the industry and Aenova very well. We wish him every success in his new role," explains Jan Kengelbach, CEO of the Aenova Group.



[Caption.]

The new Managing Director at Aenova's Marburg site, Dr. Hanno Scheffczik (Photo: Aenova)

**Aenova Group**

The Aenova Group is a leading global contract manufacturer and development service provider for the pharmaceutical and healthcare industry. As a one-stop store, Aenova develops, produces and packages all common dosage forms, product groups and active ingredient classes from pharmaceuticals to dietary supplements for human and animal health: solid, semi-solid and liquid, sterile and non-sterile, high and low dose, OEB 1 to 5 (Occupational Exposure Band). Approximately 4,200 employees at 16 sites in Europe and the U.S. contribute to the company's success. For more information, visit www.aenova-group.com.

Contact for inquiries:

Dr. Susanne Knabe
Head of Communication & PR
Aenova Holding GmbH
Berger Straße 8-10
D-82319 Starnberg

Tel: +49 8151 9987-135
Mobile: +49 170 22 368 42
E-mail: susanne.knabe@aenova-group.com